Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | IDH2 R140Q IDH2 E343V |
Therapy | Enasidenib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH2 R140Q IDH2 E343V | acute myeloid leukemia | predicted - resistant | Enasidenib | Case Reports/Case Series | Actionable | In a clinical case study, IDH2 E343V was identified as an acquired mutation in a patient with acute myeloid leukemia harboring IDH2 R140Q upon progression on Idhifa (enasidenib) (PMID: 36222845). | 36222845 |
PubMed Id | Reference Title | Details |
---|---|---|
(36222845) | Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. | Full reference... |